## Mirum Pharmaceuticals (MIRM) Earnings Preview: What to Expect on November 12th
Mirum Pharmaceuticals (MIRM), a biopharmaceutical company focused on developing treatments for rare and orphan diseases, is poised to release its quarterly earnings on Tuesday, November 12th. As investors gear up for the announcement, anticipation is high for both strong earnings results and positive guidance for the upcoming quarter.
Earnings Expectations and Market Reactions:
Analysts are projecting an earnings per share (EPS) of $-0.43 for Mirum Pharmaceuticals. While earnings performance is crucial, market reactions are often heavily influenced by the company’s guidance for the next quarter. Investors will be closely watching for signs of positive momentum and growth projections.
A Look Back at Past Performance:
Mirum Pharmaceuticals’s recent history provides valuable context for upcoming earnings. In the last quarter, the company missed EPS estimates by $0.05, but this was followed by a 2.34% increase in share price the next day. Examining the company’s past performance can shed light on potential market reactions to this upcoming announcement.
| Quarter | EPS Estimate | EPS Actual | Price Change % |
|—|—|—|—|
| Q2 2024 | -0.47 | -0.52 | 2.0% |
| Q1 2024 | -0.48 | -0.54 | 3.0% |
| Q4 2023 | -0.24 | -0.66 | -1.0% |
| Q3 2023 | -0.65 | -0.57 | 6.0% |
Share Performance and Long-Term Outlook:
As of November 8th, shares of Mirum Pharmaceuticals were trading at $42.0. Over the past 52 weeks, shares have climbed by 39.98%. This positive trajectory suggests that long-term shareholders are generally optimistic going into the earnings release.
Analyst Sentiment and Price Targets:
Understanding market sentiment is critical for investors. The consensus rating for Mirum Pharmaceuticals is Buy, based on 2 analyst ratings. The average one-year price target is $57.5, representing a potential 36.9% upside.
Peer Comparison and Financial Analysis:
To gain further insight into Mirum Pharmaceuticals’s performance and market position, we can compare it to its key industry peers, Recursion Pharmaceuticals and Galapagos.
| Company | Consensus Rating | Average 1-Year Price Target | Upside/Downside Potential |
|—|—|—|—|
| Mirum Pharmaceuticals | Buy | $57.5 | 36.9% Upside |
| Recursion Pharmaceuticals | Buy | $9.0 | 78.57% Downside |
| Galapagos | Neutral | $27.0 | 35.71% Downside |
Key Takeaways from Peer Analysis:
*
Revenue Growth:
Mirum Pharmaceuticals boasts the highest revenue growth among its peers, achieving a 107.68% growth rate over the past three months.*
Gross Profit Margin:
Despite strong revenue growth, Mirum Pharmaceuticals has the lowest gross profit margin, indicating potential challenges in cost management.*
Return on Equity:
Mirum Pharmaceuticals’s Return on Equity (ROE) is the lowest, suggesting difficulties in efficiently utilizing equity capital.About Mirum Pharmaceuticals:
Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel therapies for debilitating rare and orphan diseases. Its key product, Livmarli, is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). The company is also actively developing therapies for other rare liver diseases.
Mirum Pharmaceuticals: A Financial Deep Dive:
*
Market Capitalization:
Mirum Pharmaceuticals’s market capitalization is currently below industry benchmarks, potentially reflecting factors such as growth expectations or operational capacity.*
Revenue Growth:
Mirum Pharmaceuticals’s revenue growth has been strong, with a 107.68% increase in revenue over the past three months. However, its growth rate is lower than the average for companies in the Health Care sector.*
Net Margin:
Mirum Pharmaceuticals’s net margin is exceptional, exceeding industry averages. This signifies strong profitability and effective cost management.*
Return on Equity (ROE):
Mirum Pharmaceuticals’s ROE is below industry standards, indicating potential challenges in generating satisfactory returns for shareholders.*
Return on Assets (ROA):
Mirum Pharmaceuticals’s ROA is exceptional, surpassing industry averages. This showcases efficient use of assets and strong financial health.*
Debt Management:
Mirum Pharmaceuticals’s debt-to-equity ratio is higher than the industry average. This indicates a higher level of financial risk as the company relies heavily on borrowed funds.Stay tuned for Mirum Pharmaceuticals’ earnings release on November 12th and for further analysis of the company’s performance and future prospects.
